SARASOTA, Fla., August 18, 2026
Silo Pharma, Inc. announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent application covering SPC-15, the company’s lead therapeutic program targeting post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. The development strengthens the company’s intellectual property position for SPC-15 in another major international market and follows a recent European patent grant covering the same core invention. Silo Pharma holds an exclusive license to the Canadian patent application through its broader agreement with Columbia University, providing rights to further develop, manufacture and commercialize SPC-15 globally. The Canadian patent application focuses on the use of selected serotonin 4 (5-HT4) receptor agonists for potential prevention or delay of stress-related behavioral effects and enhancement of stress resilience. For the biopharma industry, the latest development is primarily an intellectual property and development milestone, expanding potential geographic protection around Silo Pharma’s lead CNS therapeutic program.
Canadian Patent Adds Protection for SPC-15
The allowed application, titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” covers methods involving administration of selected 5-HT4 receptor agonists before exposure to a stressor. The claimed methods are directed toward potentially preventing or delaying stress-induced fear and depressive-like behaviors and enhancing stress resilience. SPC-15 is being developed as an intranasal 5-HT4 receptor agonist, with PTSD identified as its primary development focus alongside other stress-induced psychiatric disorders. Silo Pharma said corresponding intellectual property is either granted or progressing through examination in multiple international markets, with the recent European patent grant providing additional protection for the same underlying invention. The expanding IP portfolio is strategically relevant because patent protection can help establish a longer-term development and commercialization position around a therapeutic candidate while the underlying clinical and regulatory program progresses. The Canadian Notice of Allowance therefore represents an important step in Silo Pharma’s broader effort to establish international patent coverage for SPC-15.
SPC-15 Development Targets PTSD and Stress Disorders
Silo Pharma is developing SPC-15 as part of a broader pipeline focused on underserved conditions involving the central nervous system, chronic pain and stress-induced psychiatric disorders. The company’s approach combines licensed intellectual property with therapeutic development programs intended to address areas where treatment options remain limited. For SPC-15, the company has identified PTSD as a key target indication and is pursuing an intranasal formulation based on the 5-HT4 receptor mechanism. The newly allowed Canadian claims relate primarily to the prophylactic and stress-resilience potential of the underlying pharmacological approach rather than establishing clinical efficacy. This distinction is important because a patent allowance does not demonstrate that SPC-15 is effective or safe in patients. Instead, the latest milestone strengthens the legal and commercial framework surrounding the program while Silo continues its development activities. The company has also indicated that it intends to pursue the FDA 505(b)(2) regulatory pathway for SPC-15, a strategy that may potentially streamline development by allowing reliance, where applicable, on existing information about previously established drugs or components.
Advertisement
Global IP Strategy Supports Future Development
The Canadian development adds another layer to Silo Pharma’s global intellectual property strategy for SPC-15, following the company’s recent European patent grant and advancing coverage in other international markets. Silo Pharma’s exclusive licensing relationship with Columbia University gives the company rights to develop, manufacture and commercialize SPC-15 globally under the applicable license arrangements. The company said the expanding patent estate is intended to provide broader protection as it advances its lead therapeutic program. Beyond SPC-15, Silo Pharma’s pipeline includes SP-26, a program being investigated for fibromyalgia and chronic pain, as well as a preclinical Alzheimer’s disease asset. While the Canadian Notice of Allowance does not itself represent a clinical or regulatory approval, it strengthens the IP foundation supporting SPC-15 and could become strategically important if the program progresses successfully through future development stages. The company’s immediate significance for the biopharma sector is therefore centered on patent protection, licensed CNS technology and regulatory development strategy for a potential novel PTSD treatment.
Source: Silo Pharmapress relese
